Inicio > Endocrinología y Nutrición > Novedosos aspectos fisiopatológicos de la diabetes mellitus tipo 2 > Página 5

Novedosos aspectos fisiopatológicos de la diabetes mellitus tipo 2

libres y citoquinas pro inflamatorias, y donde secreción de glucagón la convierte en una paracrinopatía unida a una asociación genómica donde se ha identificado un amplio número de variantes genéticas, que unido a la acción de las incretinas, junto a las alteraciones del metabolismo de los aminoácidos con altas concentraciones de algunos, la convierten en un síndrome multifactorial, entonces la etiología de la diabetes mellitus tipo 2, en fin parece involucrar complejas interacciones entre los factores medioambientales y genéticos, desde al ambiente intra utero, la velocidad de aumento de peso infantil y una amplia asociación genómica. La más reciente declaración de la Asociación Americana de la Diabetes y la Asociación europea para el Estudio y Manejo de la Diabetes propone la adecuación de la terapia a cada paciente, olvidando los viejos algoritmos, haciendo hincapié con el paciente para los necesarios cambios en el estilo de vida y adecuación al fenotipo del enfermo.

Referencias bibliográficas

  1. Diagnosis and classification of diabetes mellitus. Diabetes Care. Jan 2010;33; Suppl 1:S62-9.
  2. American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care. Jan 2012;35; Suppl 1:S11-63..
  3. S. Preventive Services Task Force. [Internet]Screening for Type 2 Diabetes Mellitus in Adults. [Último acceso 2 marzo 2014] 2013; Disponible en http://www.ahrq.gov/clinic/uspstf/uspsdiab.htm.
  4. Keller DM. [Internet] New EASD/ADA Position Paper Shifts Diabetes Treatment Goals. Medscape Medical News. [Último acceso 2 marzo 2014] 2013; Disponible en; http://www.medscape.com/viewarticle/771989.
  5. Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab. Feb 2011;96(2):447-53
  6. S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.[Internet] National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States,[Último acceso 2 marzo 2014] 2011. Disponible en; http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
  7. Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care. Oct 2010;33(10);2225-31.
  8. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. Jun 2012;55(6);1577-96
  9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. Jun 2012;35(6):1364-79..
  10. American Diabetes Association Professional Practice Committee. American Diabetes Association clinical practice recommendations: 2013. Diabetes Care. January 2013;36 (suppl 1):S1-S110
  11. Nathan DM, Buse, JB, Davidson MB. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711–21,.
  12. Zhang P, et al: Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:293–301.
  13. National Institute of Diabetes and Digestive and Kidney Diseases. [Internet] National Diabetes Statistics, [Último acceso 2 marzo 2014]2011. National Diabetes Information Clearinghouse. Disponible en; http://diabetes.niddk.nih.gov/dm/pubs/statistics/.
  14. Philippe MF, Benabadji S, Barbot-Trystram L, Vadrot D, Boitard C, Larger E. Pancreatic volume and endocrine and exocrine functions in patients with diabetes. Pancreas. Apr 2011;40(3):359-63.
  15. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. Mar 14 2011;171(5):404-10.
  16. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. Jan 20 2009;53(3):298-304
  17. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A. Sep 14 2010;107(37):16009-12.
  18. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. Feb 2010;42(2):142-8.
  19. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. Apr 2011;17(4):448-53
  20. Wheeler E, Barroso I. Genome-wide association studies and type 2 diabetes. Brief Funct Genomics. Mar 2011;10(2):52-60
  21. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010 Nov;1212:59-77.
  22. Ukkola O, Sun G, Bouchard C. Insulin-like growth factor 2 (IGF2 ) and IGF-binding protein 1 (IGFBP1) gene variants are associated with overfeeding-induced metabolic changes. Diabetologia. Dec 2001;44(12):2231-6.
  23. Chiefari E, Tanyolaç S, Paonessa F, Pullinger CR, Capula C, Iiritano S, et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA. Mar 2 2011;305(9):903-12.
  24. Testa R, Olivieri F, Sirolla C, Spazzafumo L, Rippo MR, Marra M, et al. Leukocyte telomere length is associated with complications of type 2 diabetes mellitus. Diabet Med. Nov 2011;28(11):1388-94.
  25. Lindgren CM, McCarthy MI. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat Clin Pract Endocrinol Metab. Mar 2008;4(3):156-63
  26. Wei GS, Coady SA, Goff DC Jr, Brancati FL, Levy D, Selvin E, et al. Blood pressure and the risk of developing diabetes in african americans and whites: ARIC, CARDIA, and the framingham heart study. Diabetes Care. Apr 2011;34(4):873-9.
  27. Slining MM, Kuzawa CW, Mayer-Davis EJ, Adair LS. Evaluating the indirect effect of infant weight velocity on insulin resistance in young adulthood: a birth cohort study from the Philippines. AmJ Epidemiol. Mar 15 2011;173(6):640-8.
  28. Ludwig J, Sanbonmatsu L, Gennetian L, Adam E, Duncan GJ, Katz LF, et al. Neighborhoods, obesity, and diabetes–a randomized social experiment. N Engl J Med. Oct 20 2011;365(16):1509-19.
  29. Hectors TL, Vanparys C, van der Ven K, Martens GA, Jorens PG, Van Gaal LF, et al. Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia. Jun 2011;54(6):1273-90.
  30. Dungan KM. Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes. Program and abstracts of the American Diabetes Association (ADA) 73rd Scientific Sessions®; June 21-25, 2013; Chicago, Illinois. Abstract 315-OR.
  31. Healy SJ, Black D, Harris C, Dungan KM. Relationship between diabetes education and readmissions in patients with hemoglobin A1c>9%. Program and abstracts of the American Diabetes Association (ADA) 73rd Scientific Sessions®; June 21-25, 2013; Chicago, Illinois. Abstract 311-OR.
  32. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. Feb 22 2007;445(7130):881-5
  33. Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. Nov 22 2010;170(21):1884-91..
  34. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia. Dec 2010;53(12):2480-6..
  35. Lindgren CM, McCarthy MI. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat Clin Pract Endocrinol Metab. Mar 2008;4(3):156-63.
  36. Wei GS, Coady SA, Goff DC Jr, Brancati FL, Levy D, Selvin E, et al. Blood pressure and the risk of developing diabetes in african americans and whites: ARIC, CARDIA, and the framingham heart study. Diabetes Care. Apr 2011;34(4):873-9.
  37. Go AS, Bauman M, Coleman King SM, An effective approach to high blood pressure control: A science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. [Internet] Hypertension [Último acceso marzo 2014]2013; Disponible en: http://hyper.ahajournals.org.
  38. Ismail-Beigi, Moghissi E, Tiktin M. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554–9.
  39. Wientjens WJHM. International charter of rights and responsibilities of people with diabetes. Br J Diabetes Vasc Dis 2009;9:105–6.
  40. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. Jun 12 2008;358(24):2630-3.
  41. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes Int J Clin Pract 2011;65:314–22.
  42. Day C. Individualised Treatment of Hyperglycaemia. British Journal of Diabetes and Vascular Disease. 2012;12(3):146-151
  43. Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycaemia in type 2 diabetes: a patient-centred approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577–96
  44. Nickerson, S, Rader, AJ. Nerve Decompression After Diabetic Foot Ulceration May Protect Against Recurrence. J Am Podiatr Med Assoc 2014; 104(1): 66–70
Páginas: 1 2 3 4 5